Global Gastroenterology Market Report and Forecast 2024-2032

Global Gastroenterology Market Outlook

The global gastroenterology market size attained a value of USD 54.59 billion in 2023. The market is anticipated to grow at a CAGR of 6.2% during the forecast period of 2024-2032. The market is likely to attain a value of USD 93.80 billion by 2032, likely to be driven by the rising gastrointestinal cases across the globe.

Gastroenterology: Introduction

A medical condition involving stomach and other organs of the digestive process are known as gastric conditions. The digestive system includes gastrointestinal tract, which is also known as the GI tract, comprising the esophagus, stomach, small intestine, large intestine, and the accessory organs of digestion, which include the pancreas, gallbladder, and liver. The branch of medicine which deals with the examination, diagnosis, and treatment of the issues related to these parts is known as gastroenterology.

In order to move material through the GI tract, digest it, absorb nutrients for use by the body, and remove waste from the body through defecation, the digestive system must function efficiently. Due to the similarity of many of the symptoms and the time-consuming nature of the diagnostic procedures, diagnosing a gastrointestinal illness may be difficult.

Global Gastroenterology Market Analysis

The increasing awareness among people about the importance of early diagnosis of gastrointestinal disorders and about available treatments is directly influencing the market growth. The increasing shift towards minimally invasive surgical procedures is also driving the market growth as people are preferring them more among other approaches. The continuous development in the diagnosis procedure of gastrointestinal disorders is also propelling the market growth.

The integration and development of technologically advanced imaging techniques, such as fluoroscopy, is also adding up significant growth to the overall gastroenterology market share. The continuous development of endoscopy devices is anticipated to accelerate the market growth further. The increasing preference for personalized treatment approaches is also expected to drive the market demand as a personalized molecular diagnosis will enable the healthcare professional to retrieve more useful diagnosis data for individuals, with the ability to produce a personalized prognosis and treatment approaches.

The increasing number of approvals is also expected to escalate the market growth. For example, the Vowst has been approved by the FDA as the first oral microbiota biotherapeutic for recurrent C. difficile infection in adults, following antibacterial treatment. The increasing government initiatives towards accessible healthcare is also aiding the growth of the market. The first drug to cure functional constipation in children and the first oral product to cure moderately to severely active Crohn’s disease has also been approved by the FDA recently, further escalating the global gastroenterology market development. There has been a surge in the market due to increase in development and manufacturing gastrointestinal drugs globally, which is further anticipated to propel the market growth. Various drugs are currently in the pipeline to be approved, including 16 oral drugs and six injectables in the pipeline. There are six drugs for breast cancer and three for non-small cell lung cancer (NSCLC) in the pipeline. Once approved, these drugs can potentially improve the treatment landcape.

Global Gastroenterology Market Segmentations

Market Breakup by Product Type

• Drugs 
  • Proton Pump Inhibitor 
  • H2 Antihistamine 
  • Others 
• Medical Devices
  • Endoscopy Devices 
  • Therapeutic devices 
  • Others 
• Diagnostic Tools 

• Others

Market Breakup by Indications

• Inflammatory Bowel Disease (IBD)

• Gastroesophageal Reflux Disease (GERD) 

• Colorectal Cancer 

• Liver Diseases

• Pancreatic Disorders

• Others

Market Breakup by End User

• Hospitals

• Ambulatory Surgical Centers

• Specialty Clinics

• Research Institutes

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Gastroenterology Market Overview

The market is experiencing significant growth due to the rising prevalence of pancreatic disorders across the globe. People are adapting to sedentary lifestyle, including unhealthy eating habits and non-active lifestyle, which leads to digestion issues, gastrointestinal issues, among others. The increasing numbers of gastrointestinal disorders are likely to drive the market growth further in the coming years.

The growth of the market is also driven by the increasing geriatric population as with growing age they get more susceptible to them due to weakened immune system. The increasing healthcare expenditure of countries globally is also driving the global gastroenterology market growth as the patient pool is large. The increasing demand for more cost effective and accessible treatments for gastrointestinal disorders such as inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and colorectal cancer, is a key factor influencing the market growth.

Gastroenterology Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Abbott Laboratories

• Johnson & Johnson

• AbbVie Inc.

• Salix Pharmaceuticals

• GlaxoSmithKline Plc.

• ALLERGAN

• Takeda Pharmaceutical Company Limited

• AstraZeneca

• Astellas Pharma US, Inc.

• Pfizer Inc. 

Key Highlights of the Report